Novartis India share price
NSE: NOVARTINDBSE: 500672Pharmaceuticals & BiotechnologySmall Cap
Novartis India Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1983
Last close ₹1,821.40down ₹26.40 (1.43%)BSE ₹1,805.95
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,847.80.
28 Oct: open ₹1,836.00, high ₹1,855.40, low ₹1,802.60
52-week range of BSE trades to 28 Oct 2026
₹750.00Low, 21 Jan 2026₹2,588.00High, 10 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,497 Cr1,055th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 46.00
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.50
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 12.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,61136.0% delivered
Results
Standalone; ₹ crore.Novartis India quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +5.4%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −4.9%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹104 Crup 14.64%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹32 Crup 27.56%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 31.0%
Revenue by quarter
Peak revenue ₹104 Cr, quarter to Jun 2026; lowest ₹84 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 87 | 93 | 84 | 88 | 90 | 86 | 91 | 104 |
| Net profit | 20 | 25 | 29 | 28 | 24 | 16 | 25 | 32 |
| Net margin | 23.4% | 27.4% | 34.9% | 31.5% | 26.8% | 18.7% | 27.9% | 31.0% |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹354 Crdown 0.54%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹93 Crdown 7.65%
- Net margin
- 26.3%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 656what Revenue, Mar 2017, includes. This period's revenue includes excise duty of ₹0.01 crore, a tax on the goods the company makes that it collects and pays to the government. | 564what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹0.01 crore, a tax on the goods the company makes that it collects and pays to the government. | 491 | 438 | 381 | 400 | 379 | 335 | 356 | 354 |
| Net profit | 57 | 78 | 52 | 10 | 21 | −4 | 103 | 85 | 101 | 93 |
| Net margin | 8.7% | 13.9% | 10.6% | 2.3% | 5.5% | −0.9% | 27.3% | 25.4% | 28.3% | 26.3% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2018: days before it are of the company before the change.Novartis India PE ratio and valuation
Price to earnings
At or below today's level on 73% of 2,431 trading days over the last 10 years.
LowestHighest
Its median29.04Industry median27.98
Price to book
At or below today's level on 98% of 1,968 trading days since Nov 2018.
LowestHighest
Its median2.47Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 3% of 2,454 trading days over the last 10 years.
LowestHighest
Its median1.59%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +23.7% | −7.7% | +33.9% | 0.0% |
| 3 years | +21.7% | −3.4% | +24.1% | 1.9% |
| 5 years | +15.1% | +34.9% | −17.0% | 3.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
8 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 3 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 2
- CutCut. Funds that held fewer shares than at the end of the month before.
- 1
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 3
| Fund | |||
|---|---|---|---|
 HDFC Pharma and Healthcare FundHDFC Mutual Fund | 1,00,627 | 0.55% | ₹19.3 Cr |
 Bandhan Healthcare FundBandhan Mutual Fund | 31,934 | 1.88% | ₹6.13 Cr |
| HDFC MNC FundHDFC Mutual Fund | 12,257 | 0.44% | ₹2.35 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 12,179 | 0.04% | ₹2.34 Cr |
 WhiteOak Capital Pharma and Healthcare FundWhiteOak Capital Mutual Fund | 11,712 | 0.24% | ₹2.25 Cr |
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 200 | 0.09% | ₹0.04 Cr |
| Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 94 | 0.09% | ₹0.02 Cr |
| Motilal Oswal BSE 1000 Index FundMotilal Oswal Mutual Fund | 21 | 0.01% | ₹40,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Novartis India insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 1 off-market move
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Novartis India competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Novartis India in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 IOL Chemicals and PharmaceuticalsIOLCP | 5,302 | 31.54 | 2.95 | +18.6% | +60.1% | 9.6% | 11.8% | 0.55% |
 Orchid PharmaORCHPHARMA | 5,180 | – | – | +26.2% | – | – | 0.2% | 0.00% |
 RPG Life SciencesRPGLIFE | 4,704 | 39.38 | 7.77 | +11.8% | −34.6% | 21.0% | 21.3% | 0.84% |
 Gujarat Themis BiosynGUJTHEM | 4,628 | 95.04 | – | +17.5% | +9.2% | 18.2% | 15.1% | 0.19% |
 SMS PharmaceuticalsSMSPHARMA | 4,453 | 43.36 | 5.67 | +10.2% | +40.4% | 14.4% | 11.5% | 0.08% |
 Zota Health CareZOTA | 4,402 | – | 7.04 | +69.0% | – | −24.0% | −16.1% | 0.08% |
 Gufic BiosciencesGUFICBIO | 4,249 | 57.85 | 6.39 | +16.7% | +18.7% | 11.6% | 12.7% | 0.02% |
 Aarti DrugsAARTIDRUGS | 4,088 | 21.38 | 2.64 | +10.5% | +1.2% | 13.1% | 12.4% | 0.45% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Novartis India dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹47.50 a share, year to Mar 2023.
| Ex-date | Type | Per share |
|---|---|---|
| 23 Jul 2025 | Final | ₹25.00 |
| 23 Jul 2024 | Final | ₹25.00 |
| 20 Jul 2023 | Final | ₹10.00 |
| 20 Jul 2023 | Special | ₹37.50 |
| 20 Jul 2022 | Final | ₹10.00 |
| 17 Aug 2021 | Final | ₹10.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Novartis India announcements
Oct 2026
8 Oct · Announcement under Regulation 30 (LODR)-Raising of Funds
8 Oct · Announcement under Regulation 30 (LODR)-Issue of Securities
8 Oct · Board meeting
Novartis India share price by year
Each calendar year to 2025.Novartis India share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025BSE close | 779.00 | −15.3% | 1,081.55 | 746.15 |
| 2024BSE close | 919.80 | +19.0% | 1,195.35 | 775.55 |
| 2023BSE close | 773.25 | +14.6% | 905.35 | 556.70 |
| 2022 | 674.55 | −13.1% | 789.45 | 573.85 |
| 2021 | 776.20 | +13.4% | 1,048.90 | 546.00 |
| 2020BSE close | 684.60 | +2.5% | 711.40 | 439.55 |
| 2019BSE close | 667.60 | −7.3% | 753.85 | 562.05 |
| 2018BSE close | 720.30 | +12.0% | 944.70 | 592.25 |
| 2017BSE close | 643.15 | −4.6% | 742.50 | 581.30 |
| 2016BSE close | 673.85 | −16.7% | 872.75 | 617.75 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,821.00 | 1,858.10 | 1,792.80 | 1,847.80 | 1,825.21 | 15,302 | 41.8% |
| 26 Oct 2026 | 1,808.10 | 1,861.90 | 1,775.60 | 1,790.20 | 1,812.63 | 24,856 | 36.9% |
| 23 Oct 2026 | 1,684.50 | 1,884.50 | 1,642.20 | 1,824.50 | 1,771.80 | 1,46,218 | 23.7% |
| 22 Oct 2026 | 1,770.00 | 1,813.80 | 1,665.00 | 1,684.50 | 1,725.10 | 55,386 | 39.3% |
| 21 Oct 2026 | 1,891.90 | 1,896.30 | 1,755.50 | 1,768.00 | 1,816.92 | 32,229 | 50.8% |
| 19 Oct 2026 | 1,888.10 | 1,940.00 | 1,869.70 | 1,921.60 | 1,906.25 | 12,000 | 49.6% |
| 16 Oct 2026 | 1,935.00 | 1,949.10 | 1,850.00 | 1,897.60 | 1,895.26 | 31,507 | 46.5% |
| 15 Oct 2026 | 1,985.00 | 1,985.00 | 1,923.40 | 1,940.10 | 1,946.60 | 22,385 | 54.2% |
| 14 Oct 2026 | 1,993.00 | 2,012.30 | 1,962.20 | 1,988.20 | 1,982.25 | 21,540 | 36.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Buyback and offer for sale history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 26 Mar 2009 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Each event is noted and not adjusted for.
Company details
- NSE symbol
- NOVARTIND
- BSE code
- 500672
- ISIN
- INE234A01025
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.novartis.in
- CIN
- L24200MH1947PLC006104
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1947
- Registered office
- The Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (E), Mumbai 400018, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments